Advanced Infusion Care (AIC), a division of AIS Healthcare, announced an agreement to conduct a joint study with Grifols, to observe the effects of subcutaneous immunoglobulin (SCIG) products on individuals living with primary immune deficiencies (PID). AIC and Grifols? Satisfaction and Outcomes in Primary Immune Deficiency patients (SOPID) study will observe 60 patients across a three-month period who are beginning SCIG therapy.
The purpose of the study is to determine if there are differences in patient experience and satisfaction with immunoglobulin treatments, which will help physicians, pharmacists, and nurses ensure patients living with immunodeficiencies receive the therapy that best fits their medical and lifestyle needs. The joint study between AIC and Grifols seeks to determine if there are differences in patient tolerability and satisfaction with immunoglobulin treatments, ensuring the best quality of care for patients living with immunodeficiencies. The results will provide physicians and patients with more information as they make decisions and plan long-term treatment strategies.